B.Riley Financial Keeps Their Buy Rating on Altimmune (ALT)


In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Altimmune (ALT), with a price target of $28.00. The company’s shares closed last Thursday at $12.27.

According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 33.0% and a 53.4% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Spectrum Pharmaceuticals.

Altimmune has an analyst consensus of Moderate Buy, with a price target consensus of $54.00.

See today’s analyst top recommended stocks >>

Based on Altimmune’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.94 million and GAAP net loss of $17.77 million. In comparison, last year the company earned revenue of $644K and had a GAAP net loss of $10.94 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.

Read More on ALT:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts